Algeria vs China: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Algeria
0.1%
in 2024
China
0.1%
in 2024
Algeria rank
112th
China rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Algeria
- China
How they compare
Algeria currently reports 0.1% against 0.1% in China, a difference of 0.0%.
Across all 10 years both countries report, China has been ahead every year.
Algeria ranks 112th and China ranks 112th of 215 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Algeria | China | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | China |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Algeria or China?
- Algeria, at 0.1% against 0.1% in China as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Algeria and China?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and China?
- 10 years are reported by both, from 2015 to 2024.
- How do Algeria and China rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Algeria ranks 112th and China ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.